Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations.
Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
Ahlqvist-Rastad
Jane
J
Medical Products Agency, Uppsala 751 03, Sweden.
Albertsson
Maria
M
Bergh
Jonas
J
Birgegård
Gunnar
G
Johansson
Peter
P
Jonsson
Bertil
B
Kjellen
Elisabeth
E
Påhlman
Sven
S
Zackrisson
Björn
B
Osterborg
Anders
A
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000075202:Contraindications; D004921:Erythropoietin / Q000378:metabolism; D005260:Female; D006397:Hematinics / Q000378:metabolism; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism / Q000401:mortality; D017410:Practice Guidelines as Topic; D017467:Receptors, Erythropoietin / Q000378:metabolism; D016019:Survival Analysis; D013548:Sweden; D017211:Treatment Failure
D006397:Hematinics; D017467:Receptors, Erythropoietin; D004921:Erythropoietin